2024 Full Year Guidance: Reaffirmed, expecting modest sequential improvement in Q2 organic sales growth and adjusted EBIT margin.
Revenue Growth: Stronger in the second half of the year.
New Product Launches: Expected to accelerate growth in ultrasound.
Expected Growth Areas: Imaging, supported by healthy backlog and large order funnel; continuing growth in PDx business; improvement in PCS backlog fulfillment challenges by mid-year.
Capital Investment: Positive sentiment among customers about capital investment and market normalization, particularly in the United States.
Healthcare Demand: Strong global procedure environment expected to continue, with a more connected, efficient, and patient-centric healthcare market.
Innovation and Investment: Continued investment in innovation, including partnerships and strategic initiatives, aimed at solving evolving customer and patient needs.
Market Challenges: Fulfillment delays and prior year comparisons as challenges; anticorruption impacts and stimulus considerations in China.
Product and Service Growth: Good growth opportunities identified in both product and service sectors, supported by a growing installed base.
”We’ve made good progress against our key priorities for 2024. Healthy backlog, orders growth and positive book-to-bill position us for accelerated growth for the rest of the year.” - Peter Arduini, President and CEO.
”Our strategic initiatives and trusted partnerships are taking hold and position us well for a future where health care is more connected, efficient and patient-centric.” - Peter Arduini.
”We’re executing on significant capacity investments to strengthen the security of supply for our customers and to deliver on our patients’ needs.” - James Saccaro, Vice President and CFO.
”We’re excited about recent product introductions across our segments to address customer challenges and improve patient outcomes.” - Peter Arduini.
